AstraZeneca

News

ESMO: Trodelvy's overall survival benefit revealed

Prospects for Gilead Sciences' Trodelvy in hormone receptor-positive, HER2-negative metastatic breast cancer continue to improve as data from the TROPiCs-02 trial strengthen, but the jury i

News

FDA gives AZ the nod for Imfinzi in biliary tract cancer

AstraZeneca's checkpoint inhibitor Imfinzi has become the first immunotherapy to be approved by the FDA for biliary tract cancer (BTC), a rare and aggressive form of cancer with limited tre

News

AZ blocks former exec from taking up role at GSK – for now

AstraZeneca has succeeded in a last-gasp effort to stop its former head of investor relations joining rival UK pharma group GSK, after winning an injunction in the High Court in London.

News

ESC22: AstraZeneca's Farxiga DELIVERs in heart failure

AstraZeneca's Farxiga reduced the risk of hospitalisation and death in people with all types of heart failure in the DELIVER trial, which could dramatically increase the population of patie

News

Amgen's Soliris biosimilar clears phase 3, but won't launch ...

Amgen has reported positive phase 3 results with its biosimilar version of AstraZeneca/Alexion's blockbuster rare disease drug Soliris, setting up a regulatory filing with the FDA.

News

End of the line for Sanofi's SERD amcenestrant as it fails f...

Sanofi has called time on breast cancer candidate amcenestrant – at one time one of its top pipeline prospects – after it missed the mark in another clinical trial.

ESMO: Trodelvy's overall survival benefit revealed

FDA gives AZ the nod for Imfinzi in biliary tract cancer

AZ blocks former exec from taking up role at GSK – for now

ESC22: AstraZeneca's Farxiga DELIVERs in heart failure

Amgen's Soliris biosimilar clears phase 3, but won't launch ...

End of the line for Sanofi's SERD amcenestrant as it fails f...

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

AstraZeneca

Editor's Picks